May 14, 2026, 11:01 PM EDT. Novo Nordisk (NYSE:NVO) shares have presented a mixed performance with a 12.6% decline year to date but a recent 16.5% rebound over the past month. The Danish pharmaceutical giant, known for its Diabetes and Obesity Care products, reported revenues of $327.8 billion and a net income of $121.96 billion. Despite a one-year total shareholder return drop of 28.5%, some analysts see it as 51.8% undervalued with a fair value estimate near $95 per share, almost double its current trading price of $45.80. However, near-term challenges like intensifying competition, pricing pressures, and potential impacts of U.S. pricing reforms on key drugs temper optimism. Investors are urged to weigh these risks alongside durable profit margins and moderated growth forecasts to assess long-term prospects.